Cytokinetics (CYTK) vs Mirum Pharmaceuticals (MIRM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Mirum Pharmaceuticals (MIRM) has outperformed Cytokinetics (CYTK) over the past year, gaining 35.5% versus a loss of 22.4%. Over five years, MIRM leads with a +616.9% price change compared with +30.1% for CYTK. Cytokinetics is the larger company by market cap ($7.07 billion vs $6.28 billion), about 1.1 times the size.
Mirum Pharmaceuticals converts more of its revenue into profit, with a net margin of -4.5% versus -891.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CYTK | MIRM |
|---|---|---|
| Share price | $50.78 | $96.13 |
| Market cap | $7.07B | $6.28B |
| 1-day change | -1.32% | +0.65% |
| YTD return | -20.08% | +21.70% |
| 1-year return | -22.40% | +35.45% |
| 5-year return | +30.11% | +616.85% |
| Forward P/E | — | 300.41 |
| EPS (TTM) | $-6.02 | $-14.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $88.04M | $521.31M |
| Revenue growth (YoY) | +376.56% | +54.74% |
| Net income (latest FY) | $-784.96M | $-23.36M |
| Operating margin | -695.44% | -4.25% |
| Net margin | -891.60% | -4.48% |
| 52-week high | $88.31 | $130.00 |
| 52-week low | $50.32 | $63.23 |
| Distance from 52-week high | -42.50% | -26.05% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +115.48% | +64.06% |
| Average volume | 2.02M | 692.51K |
| Shares outstanding | 139.30M | 65.28M |
| Employees | 673 | 470 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MIRM has outperformed CYTK by 57.9 percentage points over the past year.
- Mirum Pharmaceuticals is more profitable, keeping -4.5 cents of every revenue dollar as net income versus -891.6 cents for Cytokinetics.
- Cytokinetics grew revenue faster in its latest fiscal year (+376.56% vs +54.74%).
About Cytokinetics
CYTK stock →Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.
Health Care · Biotechnology: Pharmaceutical Preparations · 673 employees
About Mirum Pharmaceuticals
MIRM stock →Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 470 employees
CYTK vs MIRM FAQ
Which is bigger, Cytokinetics or Mirum Pharmaceuticals?
Cytokinetics (CYTK) is larger, with a market capitalization of $7.07B compared with $6.28B for Mirum Pharmaceuticals (MIRM).
Which stock has performed better over the past year, CYTK or MIRM?
MIRM returned +35.45% over the past 12 months, compared with -22.40% for CYTK (price return, excluding dividends). Past performance does not predict future results.
Are Cytokinetics and Mirum Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.